Dave and Oli share their views on what's slowing down cell therapy approval rates
In this episode, Anthony and Michael have a great chat with David Smith, President and Chief Commercial Officer of Akron Biotech and Oliver Ball, Business Development Manager at Stemmatters.
Oliver graduated with distinction from Kings College London in 2016 with a Masters in 'Cellular Therapy From Bench to Market'.
David Smith has over 20 years of experience in cell therapy and has been involved in commercialising several therapeutic products all over the globe.
It's a great conversation with two people at different stages of their cell and gene therapy career but with the same passion for seeing innovative tools come to market. Here's the link to the non-dilutive funding report in partnership with Freemind Group!
Enjoy and, as always, please share your feedback.
You can also subscribe to the audio-only version, wherever you get your podcasts: